Innovative Research Award
Mark Stovsky
Cleveland Diagnostics, Inc.,
| Mark Stovsky |
| Affiliation |
Cleveland Diagnostics, Inc. |
| Country |
United States |
| Scopus ID |
6505757427 |
| Documents |
25 |
| Citations |
527 |
| h-index |
11 |
| Subject Area |
Biochemistry, Genetics and Molecular Biology |
| Event |
Global Best Achievements Awards |
The Innovative Research Award recognizes distinguished scholarly achievements and sustained contributions to scientific advancement. Mark Stovsky of Cleveland Diagnostics, Inc. has established a notable research profile through research associated with prostate cancer diagnostics, biomarker development, molecular characterization, and translational medicine. His scholarly record reflects sustained engagement with diagnostic research and the investigation of approaches intended to improve clinical assessment and biomedical decision-making.[1]
Abstract
Mark Stovsky is a physician and biomedical researcher whose scholarly activities focus on prostate cancer diagnostics, biomarker research, and translational medicine. His research has included investigations of prostate-specific antigen and structure-based approaches for improving prostate cancer assessment. This work has contributed to the study of diagnostic technologies designed to provide information beyond conventional biomarker measurements and support clinical evaluation. Through research publications and involvement in diagnostic development, Stovsky’s profile connects clinical medicine with biochemical and molecular research. His supplied bibliometric record of 25 documents, 527 citations, and an h-index of 11 reflects sustained scholarly activity within his research area.
Keywords
Innovative Research Award, Mark Stovsky, Cleveland Diagnostics, prostate cancer, diagnostic biomarkers, prostate-specific antigen, IsoPSA, molecular diagnostics, clinical validation, translational medicine, biomedical research, biochemistry, genetics, molecular biology.
Introduction
Scientific innovation in cancer diagnostics depends on the development of reliable biomarkers and analytical approaches capable of providing clinically meaningful information. Prostate-specific antigen is an established component of prostate cancer assessment, but concentration-based interpretation can present limitations because elevated levels may occur in different prostate conditions. Research into molecular and structural characteristics of prostate-specific antigen has therefore explored alternative approaches for improving diagnostic discrimination.[2]
Research Profile
The research profile of Mark Stovsky reflects engagement with urology, cancer diagnostics, biomarker science, and biomedical innovation. His documented scholarly activities include research concerning prostate-specific antigen and diagnostic approaches intended to improve prostate cancer evaluation. The supplied Scopus record identifies 25 documents, 527 citations, and an h-index of 11 under Author ID 6505757427, providing measurable indicators of scholarly productivity and citation visibility.[1]
Research Contributions
An important component of Stovsky’s documented research concerns the investigation of prostate-specific antigen as a biomarker whose structural characteristics may provide information beyond concentration measurements. Research involving prostate-specific antigen and solvent interaction analysis explored a diagnostic assay concept for prostate cancer using urinary samples, contributing to the development of structure-oriented biomarker research.[2]
Publications
Representative research includes an investigation of prostate-specific antigen and solvent interaction analysis published in Urology, followed by clinical validation research concerning IsoPSA published in The Journal of Urology. Together, these studies illustrate a progression from diagnostic assay concepts toward clinical evaluation of structure-based prostate cancer testing.[2][3]
Research Impact
Research impact can be assessed through scholarly publication, citation activity, and contribution to subsequent scientific investigation. The supplied Scopus metrics of 527 citations and an h-index of 11 indicate measurable scholarly attention to Stovsky’s indexed publications. When considered alongside his research in prostate cancer diagnostics and biomarker development, these indicators provide evidence of sustained academic engagement within biomedical research.[1]
Award Suitability
The Innovative Research Award is intended to recognize research characterized by scholarly contribution, originality, and relevance to scientific advancement. Mark Stovsky’s documented work in prostate cancer diagnostics and biomarker research provides a relevant basis for consideration within this category. His research connects biochemical investigation with clinical applications through the study and evaluation of structure-based diagnostic approaches.[2][3]
Conclusion
Mark Stovsky’s academic profile reflects sustained involvement in biomedical research, particularly in prostate cancer diagnostics, biomarker science, and translational medicine. His documented research on prostate-specific antigen and structure-based diagnostic approaches demonstrates continued investigation of methods intended to provide clinically relevant information for cancer assessment.[2]
External Links
References
- Elsevier. (n.d.). Scopus author details: Mark Stovsky, Author ID 6505757427. Scopus.
https://www.scopus.com/pages/authors/6505757427
- Stovsky, M., et al. (2023). IsoPSA Performance Characteristics are Unaffected by 5-Alpha Reductase Inhibitors or Alpha-Blockers: Results From the IsoPSA Validation Study.
https://doi.org/10.1016/j.urology.2023.01.037
- Stovsky, M., et al. (2022). Elevated IsoPSA Selects for Clinically Significant Prostate Cancer Without a Preference for Any Particular Adverse Histopathologic or Radiographic Feature. The Journal of Urology, p150-155.
https://doi.org/10.1016/j.urology.2022.05.029